Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927085 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL6914506 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL2927087 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL21831491 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL21831861 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL28988672 | 1.00 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| Hydrochloric Acid SCHEMBL28646059 | 0.98 | SIGMAR1 (0.37) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| Trifluoroacetic Acid SCHEMBL21629613 | 0.89 | SIGMAR1 (0.33) | SIGMAR1KHK | |
| SCHEMBL15292087 | 0.83 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 | |
| SCHEMBL13993897 | 0.83 | SIGMAR1 (0.38) | SIGMAR1TSHRMAPTPRKCBBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122029167-A | Condensed heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4687883-A2 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4655298-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025106482-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025092798-A1 | FUSED HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| CN-101166756-A | Pyrimidine derivatives and their use as p2y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-23 | — | — | CN | disclosed |
| EP-1469850-A4 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | SIGMAR1 3195/4885TSHR 2869/4885MAPT 4837/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | SIGMAR1 354/4885TSHR 3279/4885MAPT 1823/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | SIGMAR1 3195/4885TSHR 2869/4885MAPT 4837/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | SIGMAR1 354/4885TSHR 3279/4885MAPT 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.